医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Shandong Fontacea Announces License Agreement with Janssen to Develop and Commercialize Anti-IL17A Monoclonal Antibody

2019年12月18日 AM01:00
このエントリーをはてなブックマークに追加


 

JINAN, Shandong, People’s Republic of China

Shandong Fontacea Pharmaceutical Co. Ltd. (“Fontacea”) announced today that it has entered into an exclusive license, development and commercialization agreement with Janssen Biotech, Inc., to develop and commercialize pharmaceutical products containing a human IgG1λ anti-human IL-17A neutralizing monoclonal antibody in People’s Republic of China (“China”) including Hong Kong Special Administrative Region (“Hong Kong”), Macao Special Administrative Region (“Macao”), the region of Taiwan (“Taiwan”) and South Korea.

“Our agreement with Janssen on the development of this novel monoclonal antibody reflects our strong interest in interleukin 17A as an important therapeutic target and our confidence that it has the potential to revolutionize the treatment of several diseases and significantly improve the quality of life for our patients,” said Mr. Yanliang Chu, CEO and president of Fontacea. “With the commitment and resources provided by our local government and investors, I believe this will be the beginning of our discovery and development of novel medicines to help patients around the world.”

About Shandong Fontacea Pharmaceutical Co. Ltd. Fontacea is a biopharmaceutical company dedicated to research, development and commercialization of innovative medicines for the global market, conveniently located in the Jining Hightech Zone, China, with a biopharmaceutical technology research & development center in Jinan. Since its inception, it is dedicated to developing medicines for patients with respiratory diseases, inflammatory & autoimmune diseases, and cancers. Its vision is to become a fully integrated biopharmaceutical company that, through both internal research and development and in-licensing/partnership programs, discovers, develops, and commercializes novel medical products in worldwide. For more information about Fontacea visit http://www.fontaceapharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20191217005604/en/

CONTACT

Media Contact: Ms Xiaoli Chai, evachai@fontacea.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作